Novome Biotechnologies, Inc.

[On Demand]
Search General Info
Search Education
Search Partnering Companies
Novome Biotechnologies is a biotechnology company focused on engineering defined activities into the human gut microbiota to treat a wide range of diseases. The Company has developed the first platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics known as Genetically Engineered Microbial Medicines (GEMMs). The Company’s lead program in hyperoxaluria will enter the clinic in Q2 2021 and is focused on the development of a live biotherapeutic product that degrades oxalate to prevent the formation of kidney stones. Additional programs are being pursued in a range of diseases, including IBD, IBS and I/O, that leverage the Company’s proprietary synthetic biology platform and expertise in the gut microbiome. Novome is backed by leading investors, including 5AM Ventures, Alta Partners and DCVC Bio.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
NOV-001
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Chief Executive Officer
Novome Biotechnologies, Inc.